fba-a20fmdv2
PeptideexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 13, 2017 (NCT03069989)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vitronectin receptor alphaBINDING AGENT
ITGAV binding agent
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc(F)cc1)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N)=O)[C@@H](C)O)C(C)C)C(C)C- Mol. weight
- 2284.63 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1908904 ↗
Also known as
- fba-a20fmdv2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03069989 | Phase 1 | Jun 13, 2017 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1